Search

Your search keyword '"Ruutu, T"' showing total 909 results
Start Over Author "Ruutu, T"
909 results on '"Ruutu, T"'

3. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Author

Waszczuk-Gajda, A., Penack, O., Sbianchi, G., Koster, L, Blaise, D., Reményi, P., Russell, N., Ljungman, P., Trneny, M., Mayer, J., Iacobelli, S., Kobbe, G., Scheid, C., Apperley, J., Touzeau, C., Lenhoff, S., Jantunen, E., Anagnostopoulos, A., Paris, L., Browne, P., Thieblemont, C., Schaap, N.P., Sierra, J., Yakoub-Agha, I., Garderet, L., Styczynski, J., Schoemans, H., Moiseev, I., Duarte, R.F., Peric, Z., Montoto, S., Biezen, A. van, Mikulska, M., Aljurf, M., Ruutu, T., Kröger, N., Morris, C., Koenecke, C., Schoenland, S., Basak, G.W., Waszczuk-Gajda, A., Penack, O., Sbianchi, G., Koster, L, Blaise, D., Reményi, P., Russell, N., Ljungman, P., Trneny, M., Mayer, J., Iacobelli, S., Kobbe, G., Scheid, C., Apperley, J., Touzeau, C., Lenhoff, S., Jantunen, E., Anagnostopoulos, A., Paris, L., Browne, P., Thieblemont, C., Schaap, N.P., Sierra, J., Yakoub-Agha, I., Garderet, L., Styczynski, J., Schoemans, H., Moiseev, I., Duarte, R.F., Peric, Z., Montoto, S., Biezen, A. van, Mikulska, M., Aljurf, M., Ruutu, T., Kröger, N., Morris, C., Koenecke, C., Schoenland, S., and Basak, G.W.

Abstract

Contains fulltext : 251609.pdf (Publisher’s version ) (Open Access), BACKGROUND: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). METHODS: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0-100 days, 101 days-1 year, and >1 year after the first transplant. RESULTS: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4-108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1-7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3-5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. CONCLUSIONS: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

Published
2022

7. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group

Author

Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A.S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J.H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., Lachance, S., Lazarus, H., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F.B., Richardson, P.G., Ruutu, T., Saber, W., Savani, B.N., Soiffer, R., Styczynski, J., Wallhult, E., Yakoub-Agha, I., Duarte, R.F., Carreras, Enric, Universitat Autònoma de Barcelona, HUS Comprehensive Cancer Center, Clinicum, Hematologian yksikkö, Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. -H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., Lachance, S., Lazarus, H., Masszi, T., Michallet, M., Nagler, A., Nichonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Saber, W., Savani, B. N., Soiffer, R., Styczynski, J., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., Carreras, E., and UAM. Departamento de Medicina

Subjects
Feature, Adult, medicine.medical_specialty, HEPATIC VENOOCCLUSIVE DISEASE, HAPLOIDENTICAL DONOR TRANSPLANTATION, Medicina, 3122 Cancers, Hepatic Veno-Occlusive Disease, Disease, Hematopoietic cell transplantation (HCT), Therapeutics, PERIPHERAL-BLOOD, law.invention, 03 medical and health sciences, 0302 clinical medicine, Polydeoxyribonucleotides, Randomized controlled trial, law, medicine, Humans, Vascular Diseases, Intensive care medicine, Transplantation, Adult patients, business.industry, Mortality rate, Consensus guideline, Hematopoietic Stem Cell Transplantation, REGIMEN-RELATED TOXICITIES, STEM-CELL TRANSPLANTATION, Hematology, Expert group, BONE-MARROW-TRANSPLANTATION, PD-1 BLOCKADE, EUROPEAN-SOCIETY, RANDOMIZED-TRIAL, 3. Good health, URSODEOXYCHOLIC ACID, 030220 oncology & carcinogenesis, Veno-occlusive disease (SOS/VOD, Veno-Occlusive Disease, Complication, business, Haematological diseases, 030215 immunology
Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). While SOS/VOD may resolve within a few weeks in the majority of patients with mild-to-moderate disease, the most severe forms result in multiorgan dysfunction and are associated with a high mortality rate (>80%). Therefore, careful surveillance may allow early detection of SOS/VOD, particularly as the licensed available drug is proven to be effective and reduce mortality. The aim of this work is to propose an international consensus guideline for the treatment and prevention of SOS/VOD in adult patients, on behalf of an international expert group, This work was made possible thanks to the support of the Association for Training, Education, Research, in Hematology, Immunology and Transplantation (ATHERIT), which received an unrestricted educational grant from JAZZ pharmaceuticals

Published
2021

12. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, and Carreras, E

Published
2015
Full Text
View/download PDF

19. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS FEASIBLE AFTER SOLID ORGAN TRANSPLANTATION: FINAL ANALYSIS BY THE EARLY COMPLICATIONS SUBCOMMITTEE OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY, EBMT: PH-P351

Author

Basak, Wladyslaw G., Wiktor-Jedrzejczak, W., Schoemans, H., Ljungman, P., Kobbe, G., Beguin, Y., Lang, P., Sykora, Walter K., te Boome, L., van Biezen, A., van der Werf, S., Mohty, M., de Witte, T., Marsh, J., Dreger, P., Kroeger, N., Duarte, R., and Ruutu, T.

Published
2014

26. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients

Author

Aalto, S.M., Juvonen, E., Tarkkanen, J., Volin, L., Haario, H., Ruutu, T., and Hedman, K.

Subjects
Organ transplant recipients -- Health aspects, Epstein-Barr virus -- Diagnosis, Epstein-Barr virus -- Research, Lymphoproliferative disorders -- Risk factors, Viremia -- Measurement, Stem cells -- Transplantation, Stem cells -- Methods, Stem cells -- Complications and side effects, Cohort analysis, Health, Health care industry
Published
2007

27. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

Author

Aoudjhane, M, Labopin, M, Gorin, N C, Shimoni, A, Ruutu, T, Kolb, H-J, Frassoni, F, Boiron, J M, Yin, J L, Finke, J, Shouten, H, Blaise, D, Falda, M, Fauser, A A, Esteve, J, Polge, E, Slavin, S, Niederwieser, D, Nagler, A, and Rocha, V

Published
2005
Full Text
View/download PDF

30. Serum osteoprotegerin and receptor activator of nuclear factor-IoB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Author

Kananen, K., Volin, L., Laitinen, K., Ruutu, T., and Valimaki, M.J.

Subjects
Osteoporosis -- Causes of, Osteoporosis -- Care and treatment, Stem cells -- Transplantation, Stem cells -- Complications and side effects, Health
Abstract

Byline: K. Kananen (1), L. Volin (2), K. Laitinen (3), T. Ruutu (2), M. J. Valimaki (1) Keywords: Osteoporosis; Osteoprotegerin; sRANKL; Stem cell transplantation Abstract: Purpose: Osteoporosis is a long-term complication of allogeneic stem cell transplantation (SCT). Receptor activator of nuclear factor-IoB ligand (RANKL) increases osteoclast activity, while osteoprotegerin (OPG) neutralizes RANKL. A deficiency of OPG or an excess of RANKL may contribute to post-SCT bone loss. Methods: Serum OPG and soluble RANKL (sRANKL) concentrations were determined in 30 patients who received calcium, vitamin D and sex steroids -- with or without pamidronate -- prior to SCT and 1, 3, 6, and 12 months post-SCT and compared to those in healthy controls. Results: Despite all treatments patients lost bone at the hip. At baseline, serum OPG was similar in patients and controls in the two patient groups it increased by 26--27% at 6 months post-SCT (p=0.002--0.028) and over the control level (p=0.002). Serum sRANKL concentrations were also similar in patients and controls at baseline. In those patients receiving pamidronate sRANKL concentrations decreased by 42% (p=0.0007) at 3 months post-SCT. The findings on the effect of SCT on OPG and sRANKL serum levels were ascertained in 28 additional patients who did not receive pamidronate, at a median of 122 days after SCT. In this latter group, OPG but not sRANKL concentrations were clearly elevated (p&lt 0.001) in comparison to healthy controls. In conclusion, the present study fails to support the view that an excess of sRANKL or a deficiency of OPG would have a substantial impact on bone loss in SCT-recipients. Conclusion: Serum sRANKL concentrations may be modulated by bisphosphonates. Author Affiliation: (1) Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, 00290, Helsinki, Finland (2) Division of Haematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (3) Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland Article History: Registration Date: 11/11/2005 Received Date: 30/06/2005 Accepted Date: 09/11/2005 Online Date: 31/12/2005

Published
2006

36. Prophylaxis and treatment of graft-versus-host disease: EBMT - ELN working group recommendations for a standardized practice: 296

Author

Ruutu, T., Gratwohl, A., de Witte, T., Apperley, J., Bacigalupo, A., Dazzi, F., Dreger, P., Duarte, R. F., Finke, J., Garderet, L., Greinix, H. T., Holler, E., Kröger, N., Lawitschka, A., Mohty, M., Nagler, A., Passweg, J., Ringdén, O., Socié, G., Sierra, J., Stankevich, J., Sureda, A., Wiktor-Jedrzejczak, W., Madrigal, A., and Niederwieser, D.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results